Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00752206
Other study ID # SARC012
Secondary ID D8180C00039
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 2009
Est. completion date December 2017

Study information

Verified date April 2019
Source Sarcoma Alliance for Research through Collaboration
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).


Description:

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

After complete surgical removal of their cancer, patients will be randomly assigned to receive either Saracatinib or placebo (a sugar pill) throughout the study. Patients will take Saracatinib (or placebo) once daily by mouth for a total of 364 days. The duration of treatment is divided into 13 cycles, 28 days each cycle with no breaks in between.

Patients will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. To monitor for recurrence of tumor, patients will undergo thoracic CT scans at 3-4 weeks, 6-8 weeks, at 3 months, at 6 months, at 9 months, at 12 months, then every 6 months up to 2 years, and then every year up to 5 years after starting treatment. An electrocardiogram (ECG) will be taken at 3 months, and a bone scan will be performed at 12 months.

Patients who recur in the lung while on-study and who are thought to be amenable to complete surgical resection will be able to find out if they were receiving placebo or saracatinib. Those patients who were receiving placebo may then have the option of undergoing surgical resection. If fully resected of all recurrent disease,they will be given the option of receiving oral therapy with saracatinib. Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be thirteen 28-day cycles (364 days total). If complete resection of all lung nodules is not achieved, the patient will be removed from the study.

Patients who recur in locations other than the lung while on-study will be taken off study at that time.

Blood and tumor samples for research purposes will be collected at the time the tumor is removed.

After completing all 13 cycles, patients will be followed for approximately every 3 months until 2 years from starting treatment, then approximately every 6 months until 4 years from starting treatment, and once at year 5.


Other known NCT identifiers
  • NCT00923286

Recruitment information / eligibility

Status Terminated
Enrollment 38
Est. completion date December 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 15 Years to 74 Years
Eligibility Inclusion Criteria:

- Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical removal of all lung nodules are eligible for enrollment.

- Patient with suspected recurrence of osteosarcoma but who has not had surgery is eligible for enrollment but will not be randomized to receive study medication until deemed fully eligible following surgical removal of all lung nodules.

- Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.

- Patient had recurrence of osteosarcoma in the lung following standard therapy including: adriamycin, cisplatin, ifosfamide and methotrexate.

- Patient is = 15 and < 75 years of age.

- Weight = 34 kg.

- ECOG performance score of 0-2.

- Adequate bone marrow function.

- Adequate renal function.

- Adequate hepatic function.

- Adequate cardiac function.

- Women of childbearing potential must have had a negative pregnancy test (urine or serum) = 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.

- Randomization must occur = 6 weeks after complete surgical resection.

- Patient or legal guardian has signed informed consent.

Exclusion Criteria:

- Presence of metastatic disease in other locations in addition to the lung.

- Disruption of the lung pleura by tumor.

- Paget's disease.

- Patient currently using, or has previously used CYP3A4 inducers or inhibitors within 2 to 14 days prior to the initiation of oral therapy.

- Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.

- Evidence of interstitial lung disease.

- Any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.

- Myocardial infarction within one year prior to study entry.

- Bleeding diathesis, resulting in symptomatic bleeding.

- Patient is pregnant or nursing/breast-feeding.

- Patient received chemotherapy, biological or investigational agent = 28 days prior to enrollment.

- Patient experiencing unresolved toxicity = CTCAE grade 2 (except alopecia) from previous agents.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Saracatinib
Oral Agent
Placebo
Oral Agent

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States National Cancer Institute Bethesda Maryland
United States University of Alabama Birmingham Alabama
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Florida Gainesville Florida
United States Indiana University Indianapolis Indiana
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States Children's Hospital Los Angeles Los Angeles California
United States UCLA/Mattel's Children's Hospital Los Angeles California
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States St. Jude Children's Research Hospital Memphis Tennessee
United States University of Miami Miami Florida
United States Stanford University Palo Alto California
United States UCSF San Francisco California
United States Sarcoma Oncology Center Santa Monica California
United States Seattle Cancer Care Alliance/University of Washington Medical Center Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Sarcoma Alliance for Research through Collaboration AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival Rate Among Patients Treated With Saracatinib and Placebo. To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in progression free survival. Evaluation for recurrence/progression will be made every 3 months for the 1st year, then every 6 months up to 2 years, then every year up to 5 years after starting treatment.
Secondary Change in Overall Survival With the Addition of Saracatinib to Pulmonary Metastasectomy, Versus Placebo and Pulmonary Metastasectomy To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in overall survival. 5 year overall survival
Secondary Change in Time to Treatment Failure With the Addition of Saracatinib to Pulmonary Metastasectomy, Versus Placebo and Pulmonary Metastasectomy To determine if the addition of saracatinib to pulmonary metastasectomy, versus placebo and pulmonary metastasectomy, results in a change in the time to treatment failure. Time to treatment failure is the time from randomization to treatment discontinuation. Up to 12 months
Secondary Number of Genes Identified for Prediction of Recurrence of Osteosarcoma To perform microarray analysis of tumor samples to identify a gene signature that predicts for recurrence of osteosarcoma using methodology that relies on preparation of RNA, followed by cDNA. Fluorescent labeling followed by hybridization to a DNA chip allows for quantitative scanning for hybridized complexes. Up to 12 months
Secondary Biomarkers Related to Activation of Src and Src Substrates To evaluate tumor samples for biomarkers related to activation of Src and Src substrates. Up to 12 months
Secondary Cell Lines and Murine Xenografts From Recurrent Tumor Samples To establish cell lines and murine xenografts from recurrent tumor samples. Up to 12 months
Secondary Number of Mutations Identified That May be Causative For Recurrent Osteosarcoma To perform sequencing analysis of DNA and RNA in tumor samples compared to normal blood to detect mutations that may be causative for recurrent osteosarcoma. The methodology uses transcriptome sequencing, exon re-sequencing and mate-pair end sequencing, allowing us to detect translocations. The availability of matched normal DNA in the blood will allow us to determine which changes are unique to the tumor. Up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Not yet recruiting NCT05515068 - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed NCT02383901 - A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX N/A
Active, not recruiting NCT01758666 - A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy N/A
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT01615640 - Diffusion Study on Patients With Osteosarcoma
Completed NCT00523419 - Chemotherapy for Patients With Osteosarcoma Phase 2
Completed NCT00520936 - A Study of Pemetrexed in Children With Recurrent Cancer Phase 2
Completed NCT00132158 - ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Not yet recruiting NCT04319874 - Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT05642455 - SPEARHEAD-3 Pediatric Study Phase 1/Phase 2
Recruiting NCT06117878 - Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma Early Phase 1
Not yet recruiting NCT04316091 - A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma Phase 1
Recruiting NCT03932058 - Proteomics Research of Osteosarcoma
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04040205 - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Phase 2
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03628209 - Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Phase 1/Phase 2

External Links